Literature DB >> 2397608

Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis.

G Famularo1, A Procopio, R Giacomelli, C Danese, S Sacchetti, M A Perego, A Santoni, G Tonietti.   

Abstract

We studied the sera of patients with progressive systemic sclerosis (PSS) for elevated levels of soluble interleukin-2 receptor (sIL-2R), interleukin-2 (IL-2) and interleukin-4 (IL-4). We also measured IL-2, IL-4 and B cell growth factor (BCGF) activity in supernatants of peripheral blood mononuclear cells from the same patients. The finding of elevated serum sIL-2R and IL-2, and the increased levels of IL-2, IL-4 and BCGF activity in culture supernatants indicates that T lymphocyte hyperactivity likely play a major role in PSS. The failure to detect under our experimental conditions a direct proliferative effect of recombinant IL-2 on enriched normal B cells might suggest that IL-4 is the cytokine mainly responsible of the BCGF activity recovered in PSS supernatants.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2397608      PMCID: PMC1534974          DOI: 10.1111/j.1365-2249.1990.tb05340.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  G Semenzato; L M Bambara; D Biasi; A Frigo; F Vinante; B Zuppini; L Trentin; C Feruglio; M Chilosi; G Pizzolo
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

Review 2.  Silicone and rheumatic diseases.

Authors:  L P Endo; N L Edwards; S Longley; L C Corman; R S Panush
Journal:  Semin Arthritis Rheum       Date:  1987-11       Impact factor: 5.532

3.  Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration.

Authors:  M B Kahaleh; E C LeRoy
Journal:  Ann Intern Med       Date:  1989-03-15       Impact factor: 25.391

4.  Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases.

Authors:  M N Manoussakis; G K Papadopoulos; A A Drosos; H M Moutsopoulos
Journal:  Clin Immunol Immunopathol       Date:  1989-03

5.  Polyclonal B lymphocyte activation in progressive systemic sclerosis.

Authors:  G Famularo; R Giacomelli; E Alesse; M G Cifone; S Morrone; M Boirivant; C Danese; M A Perego; A Santoni; G Tonietti
Journal:  J Clin Lab Immunol       Date:  1989-06

6.  Production of B cell-stimulating factors by B cells in patients with systemic lupus erythematosus.

Authors:  Y Tanaka; K Saito; F Shirakawa; T Ota; H Suzuki; S Eto; U Yamashita
Journal:  J Immunol       Date:  1988-11-01       Impact factor: 5.422

7.  Lymphokine regulation of inflammatory processes: interleukin-4 stimulates fibroblast proliferation.

Authors:  J G Monroe; S Haldar; M B Prystowsky; P Lammie
Journal:  Clin Immunol Immunopathol       Date:  1988-11

8.  Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition.

Authors:  J A Symons; N C Wood; F S Di Giovine; G W Duff
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

9.  Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus.

Authors:  Y P Huang; L H Perrin; P A Miescher; R H Zubler
Journal:  J Immunol       Date:  1988-08-01       Impact factor: 5.422

10.  Deficient interleukin 2 production in rheumatoid arthritis: association with active disease and systemic complications.

Authors:  G D Kitas; M Salmon; M Farr; J S Gaston; P A Bacon
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

View more
  18 in total

Review 1.  T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples.

Authors:  C Chizzolini
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization.

Authors:  R Giacomelli; P Cipriani; A Fulminis; G Barattelli; M Matucci-Cerinic; S D'Alò; G Cifone; G Tonietti
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

3.  Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation.

Authors:  G Valentini; A Baroni; K Esposito; C Naclerio; E Buommino; A Farzati; G Cuomo; B Farzati
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

4.  Imbalance of CD4+ lymphocyte subsets in patients with mixed connective tissue disease.

Authors:  H Becker; A Langrock; K Federlin
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

5.  Detection of circulating Fc epsilon R2/CD23+ monocytes in patients with rheumatic diseases.

Authors:  H Becker; P Potyka; C Weber; K Federlin
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

6.  Altered production of IgE and IgA induced by IL-4 in peripheral blood mononuclear cells from patients with IgA nephropathy.

Authors:  N Yano; M Endoh; M Miyazaki; F Yamauchi; Y Nomoto; H Sakai
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

7.  In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases.

Authors:  C Prior; P L Haslam
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

8.  CD4+ and CD8+ subsets: naive and memory cells in the peripheral blood of patients with systemic sclerosis.

Authors:  R Gorla; P Airò; A Malagoli; G Carella; E Prati; D Brugnoni; F Franceschini; R Cattaneo
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

9.  Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma.

Authors:  H Ihn; S Sato; M Fujimoto; K Kikuchi; K Takehara
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

10.  Increased circulating fibrinogen-like protein 2 in patients with systemic sclerosis.

Authors:  Koichi Yanaba; Yoshihide Asano; Shinji Noda; Kaname Akamata; Naohiko Aozasa; Takashi Taniguchi; Takehiro Takahashi; Yohei Ichimura; Tetsuo Toyama; Hayakazu Sumida; Yoshihiro Kuwano; Yayoi Tada; Makoto Sugaya; Takafumi Kadono; Shinichi Sato
Journal:  Clin Rheumatol       Date:  2012-09-16       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.